House Rx is a San Francisco–based health technology company redesigning specialty pharmacy by embedding locally owned dispensaries inside specialty clinics, shifting control away from traditional PBM-centric models. Its proprietary pharmacy management platform uses embedded AI workflows—such as the new “Smart PA” feature that automates up to 80 % of prior authorizations—to streamline operations and accelerate treatment starts. The company partners with more than 1,000 providers across 80 clinic sites nationwide and currently processes about $1.5 billion in specialty prescriptions annually, a figure it expects to double to $3 billion by 2026. By colocating pharmacists with physicians, House Rx aims to boost patient adherence, cut costs, and deliver high-touch care for complex conditions. Recent funding will allow the company to expand its in-clinic model to additional medical specialties and continue building AI-native capabilities. Management intends to scale operations rapidly to meet growing demand from providers, manufacturers, and payers. Total capital raised now stands at $100 million, providing resources for both geographic and technological expansion.

Total raised

$80M

Funding rounds

3

Latest round

Series B

Latest activity

Nov 2025